162 related articles for article (PubMed ID: 31430440)
1. Biochemical diagnostics of pancreatic cancer - Present and future.
Jelski W; Mroczko B
Clin Chim Acta; 2019 Nov; 498():47-51. PubMed ID: 31430440
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer: diagnosis and treatments.
Li HY; Cui ZM; Chen J; Guo XZ; Li YY
Tumour Biol; 2015 Mar; 36(3):1375-84. PubMed ID: 25680410
[TBL] [Abstract][Full Text] [Related]
5. Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer.
Futakawa N; Kimura W; Yamagata S; Zhao B; Ilsoo H; Inoue T; Sata N; Kawaguchi Y; Kubota Y; Muto T
J Hepatobiliary Pancreat Surg; 2000; 7(1):63-71. PubMed ID: 10982594
[TBL] [Abstract][Full Text] [Related]
6. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer.
Vasiliades G; Kopanakis N; Vasiloglou M; Zografos G; Margaris H; Masselou K; Kokosi E; Liakakos T
Int J Biol Markers; 2012 Oct; 27(3):e186-94. PubMed ID: 22865301
[TBL] [Abstract][Full Text] [Related]
7. Detection of pancreatic carcinoma: diagnostic value of K-ras mutations in circulating DNA from serum.
Theodor L; Melzer E; Sologov M; Idelman G; Friedman E; Bar-Meir S
Dig Dis Sci; 1999 Oct; 44(10):2014-9. PubMed ID: 10548352
[TBL] [Abstract][Full Text] [Related]
8. Biochemical Markers of Colorectal Cancer - Present and Future.
Jelski W; Mroczko B
Cancer Manag Res; 2020; 12():4789-4797. PubMed ID: 32606968
[TBL] [Abstract][Full Text] [Related]
9. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy.
Ge L; Pan B; Song F; Ma J; Zeraatkar D; Zhou J; Tian J
BMJ Open; 2017 Dec; 7(12):e018175. PubMed ID: 29282264
[TBL] [Abstract][Full Text] [Related]
10. [Clinical usefulness of tumor markers associated with pancreatic cancer].
Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
[TBL] [Abstract][Full Text] [Related]
11. [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer].
Dai MH; Zhao YP; Cai LX; Zhu Y
Zhonghua Wai Ke Za Zhi; 2003 May; 41(5):332-5. PubMed ID: 12892584
[TBL] [Abstract][Full Text] [Related]
12. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors in colorectal cancer patients.
Mroczko B; Szmitkowski M; Okulczyk B
Clin Chem Lab Med; 2003 May; 41(5):646-51. PubMed ID: 12812262
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer.
Urgell E; Puig P; Boadas J; Capellà G; Queraltó JM; Boluda R; Antonijuan A; Farré A; Lluís F; González-Sastre F; Mora J
Eur J Cancer; 2000 Oct; 36(16):2069-75. PubMed ID: 11044643
[TBL] [Abstract][Full Text] [Related]
15. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.
Minamoto T; Mai M; Ronai Z
Cancer Detect Prev; 2000; 24(1):1-12. PubMed ID: 10757118
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer.
Yang J; Li S; Li J; Wang F; Chen K; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Zhang H; Guo C
Pancreatology; 2016; 16(4):605-14. PubMed ID: 27237100
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.
van Es JM; Polak MM; van den Berg FM; Ramsoekh TB; Craanen ME; Hruban RH; Offerhaus GJ
J Clin Pathol; 1995 Mar; 48(3):218-22. PubMed ID: 7730480
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor markers and molecular biological diagnosis in pancreatic cancer.
Sawabu N; Watanabe H; Yamaguchi Y; Ohtsubo K; Motoo Y
Pancreas; 2004 Apr; 28(3):263-7. PubMed ID: 15084968
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers of pancreatic cancer: development and clinical relevance.
Fry LC; Mönkemüller K; Malfertheiner P
Langenbecks Arch Surg; 2008 Nov; 393(6):883-90. PubMed ID: 18266003
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice.
Uehara H; Nakaizumi A; Baba M; Iishi H; Tatsuta M; Kitamura T; Ohigashi H; Ishikawa O; Takenaka A; Ishiguro S
Am J Gastroenterol; 1996 Aug; 91(8):1616-21. PubMed ID: 8759672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
